1,1,3,3-tetramethylpentylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,1,3,3-tetramethylpentylamine
• 英文别名: 2,4,4-Trimethylhexan-2-amine
• 化学式: C₉H₂₁N
• mdl: MFCD19214787
• 分子量: 143.272
• InChiKey: TZSJUPHSJLIAEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,1,3,3-tetramethylpentylamine 、 苯甲醇 在 calcium nitride 、 N,N'-bis(salicylidene)-1,2-cyclohexanediaminomanganese(III) chloride 作用下， 以 甲苯 为溶剂， 反应 48.0h， 以69%的产率得到
  参考文献：
  名称：

  锰（iii）salen催化的醇脱氢的开发和机理研究†

  摘要：

  介绍了用于醇的无受体脱氢的锰 ( III ) 催化剂的第一个例子。N , N' -双(水杨基)-1,2-环己烷二氨基锰 ( III ) 氯化物 ( 2 ) 已被证明可催化从各种醇和胺直接合成亚胺，并释放氢气。该机制已经用标记的底物进行了实验研究，并在理论上用 DFT 计算进行了研究。结果表明金属-配体双功能途径，其中salen配体中的两个亚胺基团首先被还原形成锰（III) 酰胺络合物作为催化活性物质。然后通过逐步的外球氢转移发生醇的脱氢，产生氢化锰( III )，从中释放氢气。

  DOI：

  10.1039/c8sc03969k

文献信息

• [EN] UREA DERIVATIVES OF AMPHOTERICIN B DERIVED FROM SECONDARY AMINES<br/>[FR] DÉRIVÉS D'URÉE DE L'AMPHOTÉRICINE B DÉRIVÉE D'AMINES SECONDAIRES
  申请人：UNIV ILLINOIS

  公开号：WO2016112243A1

  公开（公告）日：2016-07-14

  Provided are certain urea derivatives of amphotericin B (AmB) having improved therapeutic index compared to AmB. The compounds of the invention are less toxic than AmB and are useful to treat fungal infections. In certain embodiments the urea derivative of AmB is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: wherein, independently for each occurrence: R represents methyl, ethyl, propyl, or isopropyl; R' represents methyl, ethyl, propyl, or isopropyl; or R and R', taken together with the nitrogen atom to which they are attached, represent a radical of a cyclic secondary amine. Also provided are methods for making the urea derivatives of AmB.

  提供了与两性霉素B（AmB）相比具有改善的治疗指数的某些尿素衍生物。本发明的化合物比AmB毒性更小，并且可用于治疗真菌感染。在某些实施例中，AmB的尿素衍生物是由以下式（I）表示的化合物或其药用可接受的盐：其中，对于每次出现独立地：R代表甲基、乙基、丙基或异丙基；R'代表甲基、乙基、丙基或异丙基；或R和R'与它们连接的氮原子一起表示环状二级胺的基团。还提供了制备AmB的尿素衍生物的方法。
• Dyes That are Soluble in Organic Solvents
  申请人：Ruch Thomas

  公开号：US20080184497A1

  公开（公告）日：2008-08-07

  The present invention relates to dyes of formula (1) that are soluble in organic solvents, wherein Cat + is an organic cation, to a process for their preparation and to their use in the production of coloured plastics or polymeric colour particles, printing colorants, printing pastes and printing inks.

  本发明涉及式(1)的染料，其在有机溶剂中可溶，其中Cat+是有机阳离子，还涉及它们的制备方法及其在有色塑料或聚合物彩色颗粒、印花着色剂、印花浆和印刷油墨生产中的用途。
• [EN] COMPOUNDS FOR OPTICALLY ACTIVE DEVICES<br/>[FR] COMPOSÉS POUR DISPOSITIFS OPTIQUEMENT ACTIFS
  申请人：MERCK PATENT GMBH

  公开号：WO2017032442A1

  公开（公告）日：2017-03-02

  The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.

  本发明涉及新型化合物，特别是包含光活性单元的化合物，这些新型化合物特别适用于眼科设备，以及包含这些化合物的眼科设备。
• [EN] NOVEL ANTIBACTERIAL 3"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS<br/>[FR] NOUVEAUX DÉRIVÉS 3" ANTIBACTÉRIENS D'ANTIBIOTIQUES À BASE D'AMINOGLYCOSIDE 2,5-DIDÉSOXYSTREPTAMINE 4,6-DISUBSTITUÉS
  申请人：AGILEBIOTICS B V

  公开号：WO2020115190A1

  公开（公告）日：2020-06-11

  The present invention relates to novel aminoglycoside compounds having antimicrobial properties and being suitable, for example, as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The invention further relates to compounds for use in the treatment of diseases whose treatment is made otherwise difficult due to antibiotic-class-related bacterial resistance and provides novel therapeutic agents suitable for use in the treatment of multidrug-resistant (MDR) infections.

  本发明涉及具有抗微生物特性的新型氨基糖苷化合物，适用于作为治疗剂，例如用于治疗哺乳动物疾病的治疗剂，特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述治疗剂的药物组合物在治疗哺乳动物的医疗状况中的使用，特别是在治疗微生物感染中的使用。本发明的治疗剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊意义。本发明还涉及用于治疗因抗生素类相关细菌耐药而导致治疗变得困难的疾病的化合物，并提供适用于治疗多药耐药（MDR）感染的新型治疗剂。
• PHOTOCURABLE COMPOSITION
  申请人：Fukui Hiroji

  公开号：US20110097669A1

  公开（公告）日：2011-04-28

  The present invention provides a photocurable composition which contains a photobase generator capable of generating a satisfactory amount of a base in a high quantum yield when irradiated even with a small quantity of light for a short time, and contains a curable compound that is rapidly cured by the generated base such that the composition is cured into a cured product. The photocurable composition comprises: a photobase generator (A) which is a salt of a carboxylic acid (a1-1) represented by the following formula (1-1) with a basic compound (a2), and a curable compound (B) which has, in one molecule thereof, at least two functional groups selected from among epoxy group, (meth)acryloyl group, isocyanato group, acid anhydride group, and alkoxysilyl group, where R1 to R7 in the above formula (1-1) each are hydrogen or an organic group, R1 to R7 may be the same or different, and two of R1 to R7 may be bonded to each other to form a ring structure.

  本发明提供了一种光固化组合物，其包含一种光碱发生剂，当短时间内用少量光照射时，能够生成足量碱，并且具有高量子产率，同时含有一种可固化化合物，该化合物能够被生成的碱迅速固化，从而使组合物固化成为固化产物。该光固化组合物包括：光碱发生剂（A），其是由下式（1-1）所表示的羧酸盐（a1-1）与碱性化合物（a2）形成的，以及一种可固化化合物（B），该化合物在一个分子中具有至少两种官能团，所述官能团选自环氧基团、（甲基）丙烯酰基团、异氰酸酯基团、酸酐基团和烷氧基硅基团，其中上述式（1-1）中的R1至R7分别为氢或有机基团，R1至R7可以相同或不同，其中两个R1至R7可以相互连接形成环结构。